Alpha adrenergic antagonist: Difference between revisions
imported>Robert Badgett (→Costs: Added costs for Doxazosin) |
imported>Howard C. Berkowitz No edit summary |
||
| (2 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
In [[pharmacology]], '''alpha adrenergic blockers''' are "drugs that bind to but do not activate alpha-[[adrenergic receptor]]s thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of [[hypertension]], vasospasm, [[peripheral arterial disease|peripheral vascular disease]], [[shock]], and [[pheochromocytoma]]."<ref>{{MeSH}}</ref> They are also used for [[benign prostatic hyperplasia]]. | {{subpages}} | ||
In [[pharmacology]], '''alpha adrenergic blockers''' are "drugs that bind to but do not activate alpha-[[adrenergic receptor]]s thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of [[hypertension]], vasospasm, [[peripheral arterial disease|peripheral vascular disease]], [[shock]], and [[pheochromocytoma]]."<ref>{{MeSH}}</ref> They are also used for [[benign prostatic hyperplasia]]. | |||
Naftopidil is more selective for the alpha-1a [[adrenergic receptor]] and has been used to treat [[benign prostatic hyperplasia]].<ref name="pmid19821408">{{cite journal| author=Garimella PS, Fink HA, Macdonald R, Wilt TJ| title=Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. | journal=Cochrane Database Syst Rev | year= 2009 | volume= | issue= 4 | pages= CD007360 | pmid=19821408 | Naftopidil is more selective for the alpha-1a [[adrenergic receptor]] and has been used to treat [[benign prostatic hyperplasia]].<ref name="pmid19821408">{{cite journal| author=Garimella PS, Fink HA, Macdonald R, Wilt TJ| title=Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. | journal=Cochrane Database Syst Rev | year= 2009 | volume= | issue= 4 | pages= CD007360 | pmid=19821408 | ||
Latest revision as of 11:04, 11 June 2010
In pharmacology, alpha adrenergic blockers are "drugs that bind to but do not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous adrenergic agonists. Adrenergic alpha-antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma."[1] They are also used for benign prostatic hyperplasia.
Naftopidil is more selective for the alpha-1a adrenergic receptor and has been used to treat benign prostatic hyperplasia.[2] Vascular drug toxicity may be less with tamsulosin due to more selectivity to α1-A and α1-D adrenergic receptors according to a meta-analysis supported by Boehringer Ingelheim Pharmaceuticals, the maker of tamsulosin.[3]
Costs
According to drugstore.com:
- Alfuzosin (Uroxatral) 10 mg - $121.85 for 30 tablets
- Doxazosin (Cardura) 8 mg - $23.99 for 30 tablets
- Naftopidil
- Prazosin (Minipress) 5 mg - $33.99 for 60 tablets
- Tamsulosin (Flomax) 0.4 - $142.19 for 30 tablets
- Terazosin
References
- ↑ Anonymous (2024), Alpha adrenergic antagonist (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Garimella PS, Fink HA, Macdonald R, Wilt TJ (2009). "Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.". Cochrane Database Syst Rev (4): CD007360. DOI:10.1002/14651858.CD007360.pub2. PMID 19821408. Research Blogging.
- ↑ Nickel JC, Sander S, Moon TD (2008). "A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.". Int J Clin Pract 62 (10): 1547-59. DOI:10.1111/j.1742-1241.2008.01880.x. PMID 18822025. PMC PMC2658011. Research Blogging.